Gallium phosphinoarylbisthiolato complexes counteract drug resistance of cancer cells.

In cancer therapy the platinum-based drugs are used frequently with a good clinical outcome, but besides unwanted side effects which occur, the tumour cells subjected to treatment are prone to develop tolerance or even multidrug resistance (MDR). Metal compounds with a central atom other than platinum are efficient in targeting the chemoresistant cells, therefore the biological outcome of two recently synthesized gallium phosphinoarylbisthiolato complexes was studied, having the formula [X][Ga{PPh(2-SC6H4)2-κ(3)S,S',P}{PPh(2-SC6H4)2-κ(2)S,S'}] where [X] is either the NEt3H (1) or PPh4 (2) cation. Compounds 1 and 2 display in vitro cytotoxicity against both platinum-sensitive and platinum-resistant cell lines (A2780 and A2780cis).

When arsine makes the difference: chelating phosphino and bridging arsinoarylthiolato gallium complexes.

The (organo)gallium compounds GaCl{(SC6H4-2-PPh2)-kappa2S,P}2 (1), Ga{(SC6H4-2-PPh2)-kappa2S,P}{(SC6H4-2-PPh2)-kappaS}2 (2), GaMe2{(SC6H4-2-PPh2)-kappa2S,P} (3), GatBu2{(SC6H4-2-PPh2)-kappa2S,P} (4), GatBu{(SC6H4-2-PPh2)-kappa2S,P}{(SC6H4-2-PPh2)-kappaS} (5), [GaMe2{(mu2-SC6H4-2-AsPh2)-kappaS}]2 (6), and GatBu{(SC6H4-2-AsPh2)-kappa2S,As}{(SC6H4-2-AsPh2)-kappaS} (7) were obtained from the reaction of 2-EPh2C6H4SH (E = P (PSH), As (AsSH)) with GaCl3 (1, 2) or GaR3 (R = Me, tBu; 3-7) in different molar ratios and under different reaction conditions. Compound 2 was also obtained from Li(PS) and GaCl3 (3.5:1).